non-small cell lung cancer

reshuffle pipeline target reorganize shift change
Biotech

Ose narrows focus to conserve cash at expense of wider pipeline

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
James Waldron Dec 9, 2025 9:41am
Abstract arrangement of geometric shapes including spheres a pyramid and balancing wooden and stone slabs

BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial

Dec 8, 2025 7:47am
next step ladder climb succeed win

Nuvalent races to FDA to challenge Pfizer for lung cancer market

Nov 17, 2025 7:45am
Blue race track
Favicon Fierce Pharma

Merck grows more ambitious about 'workhorse' TROP2 ADC

Oct 20, 2025 4:00pm
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am
Cancer mutation precision medicine oncology targeted

ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR

Oct 19, 2025 4:15am